Biological & Clinical Evaluation of Medical Devices

Biological evaluation is the structured assessment of how a medical device interacts with the body to demonstrate biocompatibility and safety for its intended use. It typically considers device materials, nature and duration of contact, processing residues, toxicological risks, and applicable testing or justification strategies. The work is commonly aligned with ISO 10993 principles and integrated with risk management and technical documentation.

Clinical evaluation is the systematic assessment of clinical data to confirm that a medical device achieves its intended purpose and maintains an acceptable safety profile. It may include literature, clinical investigations, PMCF data, complaint trends, and real-world evidence. The output often supports regulatory submissions by linking clinical evidence, benefit-risk conclusions, and post-market findings into a defensible evaluation record.

A device generally needs biological evaluation whenever it has direct or indirect patient contact, including skin, mucosal, blood, tissue, or implant contact. The scope depends on contact type, duration, materials, manufacturing processes, and whether the device has changed. Even when full testing is not required, manufacturers still need a documented rationale, risk-based assessment, and traceable evidence supporting biological safety.

A clinical evaluation package often includes the clinical evaluation plan, literature search strategy, appraisal records, data analysis, benefit-risk conclusions, PMCF inputs where applicable, and the final Clinical Evaluation Report. It may also reference risk management files, PMS data, labeling, intended use statements, and technical documentation sections. Strong packages are internally consistent, traceable, and aligned with the target market’s regulatory expectations.

Biological and clinical evaluations should directly support the device risk management process rather than exist as standalone documents. Biological findings inform hazard identification and residual risk conclusions, while clinical evaluation confirms whether safety and performance remain acceptable in real-world use. Regulators expect these outputs to align with ISO 14971 risk files, labeling claims, PMS data, and the broader technical documentation narrative.

In some cases, yes, but only when the literature is relevant, methodologically sound, and sufficiently representative of the device under evaluation. The evidence must support intended use, technological characteristics, clinical performance, and safety conclusions. For higher-risk, novel, or poorly documented devices, literature alone may be inadequate, and additional PMCF, clinical investigation data, or other evidence may be needed to close gaps.

Common issues include weak literature search methods, poor equivalence justification, missing traceability to risk management, outdated reports, unsupported conclusions, and gaps between claims and evidence. Regulators also challenge evaluations when biological endpoints are not justified, PMCF rationale is weak, or technical documentation is inconsistent. A structured readiness review can identify these weaknesses before submission and reduce avoidable deficiency questions.

Elexes supports manufacturers with clinical evidence strategy, CER authoring and review, PMCF adequacy review, submission readiness assessments, gap analysis, and alignment of evaluation outputs with risk management and technical documentation. The team also helps remediate weak files before FDA, EU MDR, TGA, Health Canada, and other submissions. This approach helps reduce rework, improve defensibility, and support smoother regulatory interactions.